Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Capital Expenditures (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Capital Expenditures for 7 consecutive years, with $112000.0 as the latest value for Q2 2025.

  • Quarterly Capital Expenditures rose 113.35% to $112000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $374000.0 through Dec 2025, down 90.28% year-over-year, with the annual reading at $374000.0 for FY2025, 90.28% down from the prior year.
  • Capital Expenditures for Q2 2025 was $112000.0 at Pliant Therapeutics, down from $262000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $3.4 million in Q3 2024, with the low at -$865000.0 in Q3 2022.
  • Average Capital Expenditures over 5 years is $520941.2, with a median of $248000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 34290.0% in 2024, while the deepest fall reached 8490.0% in 2024.
  • Over 5 years, Capital Expenditures stood at $1.6 million in 2021, then grew by 6.41% to $1.7 million in 2022, then tumbled by 46.67% to $921000.0 in 2023, then crashed by 77.31% to $209000.0 in 2024, then tumbled by 46.41% to $112000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $112000.0, $262000.0, and $209000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.